Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults with Asthma on Medium-to-High Dose Inhaled Corticosteroids - APATURA

Study identifier:D2912C00003

ClinicalTrials.gov identifier:NCT04643158

EudraCT identifier:2020-002828-37

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder for Four Weeks in Adults with Asthma on Medium-to-High Dose Inhaled Corticosteroids

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD1402, Placebo, Short acting beta agonist (SABA) (rescue medication), Run-in medications (ICS-LABA combination)

Sex

All

Actual Enrollment

72

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 12 Mar 2021
Primary Completion Date: 20 Jul 2023
Study Completion Date: 20 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria